GlaxoSmithKline plc (NYSE:GSK) is pleased to announce its success in line with the development of an HIV drug known as Rukobia. The business guru applauded the move by the US Food and Drug Administration, outlining that its approval of the product was a start to even better things to come for patients. The body is said to have given its approval on Thursday, and the beneficiaries will be the adult patients who have been having it hard to find some working treatment options.
The testing unit
ViiV happens to be this company’s HIV unit entrusted with the development of some diverse oral treatments for handling the deadly virus. Rukobia is set to work effectively in helping patients that have been struggling to find working solutions for handling their dilapidating health conditions. It is assumed that these patients have tried out different therapies years, and none of them has resulted in desirable results. Experts in the field say that the problem resulted from issues related to intolerance, resistance, and some other safety considerations.
It is indeed true that a great deal of antiretroviral medicines is capable of suppressing HIV. They have, over the years, been noted to do much in line with decreasing disease progression. Asides from that, they have also been doing a good job at toning down the HIV transmissions and reducing the number OF AIDS-related deaths.
Dealing with the unpredictable nature of HIV
However, even experts in the medical segment are starting to get to terms with. It is the reality that HIV keeps changing as time progresses. That is something that causes a lot of people to develop some sort of viral resistance that eventually causes many of their treatment regimens to perform poorly.
The intake of Rukobia showcased some adverse reactions that is common among most of the drugs. This drug is to be taken twice every day, common reactions include diarrhea, fatigue, and nausea.
GlaxoSmithKline plc sees the latest development as a major step forward towards achieving massive business success. It hopes to succeed in its quest to assist a large number of suffering patients globally.